Schroder Adveq

Schroder Adveq

Schroder Adveq (formerly Adveq) is an asset manager investing in private equity and real asset funds globally.

Founded in 1997, Schroder Adveq is an asset manager investing in private equity globally. Schroder Adveq invests in all private equity strategies, including venture capital, growth capital, buyout, and turnarounds through primaries, secondaries, and direct-/co-investments.


Founded in 1997, Adveq offers specialized investment solutions which allow the firm’s clients to access select private market segments globally. To date, Adveq has invested in more than 400 funds on behalf of its clients and generated consistent returns throughout economic cycles. Adveq’s client base comprises institutional investors such as pension funds, insurance companies, family offices and other financial institutions located in Europe, North America and the Asia-Pacific region. Many of Adveq’s investors are repeat, long-term clients for private market investing. Adveq has offices in Zurich, Frankfurt, London, New York, Beijing, Shanghai, and Hong Kong, as well as an agent relationship in Sydney.

As of July 31, 2017, Adveq Management AG operates as a subsidiary of Schroders plc. Adveq has been renamed Schroder Adveq through acquisition, which was announced on 20 April 2017.


The firm prefers to invest in growth capital, small/mid-market buyout and other opportunities. It seeks to invest in medicine, vaccines, medical appliances, technology, and technology-enabled services, clean energy, and health and healthcare sectors. It seeks to invest across the globe with a focus on North America, Asia / Pacific, and Europe. It also prefers to invest in China, German-speaking region, the United Kingdom, France, Benelux, and the Nordics; United States; and Canada. The firm seeks to make control investments.

For fund of funds, it seeks to invest in venture capital, private equity, distressed/turnaround, developmental capital funds, and special situation funds.

Adveq has made 7 investments. They invested $18M in Rethink Robotics on Jan 5, 2017.

Adveq has raised a total of $816.6M across 2 funds, one of them being Adveq Europe VI. This fund was announced on Dec 12, 2016, and raised a total of €462M.

Adveq has $11.5M in revenue annually. Adveq competes with AlpInvest Partners, Capital Dynamics, and Capvis Equity.


Adveq specializes in Venture and growth capital, Buyouts (value/transformational, specialist), Turnarounds, Real assets, Primaries, Secondaries, Co-investments, and Advisory services.

Schroder Adveq’s client base comprises institutional investors such as pension funds, insurance companies, endowments, family offices, and other financial institutions located in Europe, North America, and the Asia-Pacific region. For many of its clients, Schroder Adveq is a long-term partner for investments in private equity.


November 11, 2018
AMAL Therapeutics

Series B - II


October 9, 2018
ImmunOs Therapeutics

Seed - II

July 15, 2018
Pliant Therapeutics

Series B


July 11, 2018
Nohla Therapeutics

Series B - II


June 18, 2018
Decibel Therapeutics

Series C


January 4, 2017
Rethink Robotics

Series E - Rethink Robotics


December 11, 2016
Adveq Europe VI


October 23, 2016

Venture Round - AEVI


October 16, 2016

Series D -


May 3, 2016

Series D -


Page 1 of 2



Angela Kehrli

Alternatives Director

Anne-Juliane Knauer

Chief Compliance Officer

Benjamin Alt

Head of Investments DACH, Nordics & CEE

Christoph Bachmann

Alternatives Director

Daniel Rhoads

Alternatives Director, Head of North America

David Bajada

Investment Manager

David Seex

Head of Asia Pacific

Emily Pollock

Alternatives Director

Erwin Boos

Investment Director

Ethan Vogelhut

Head of Buyout Investments Americas

Ian G. Siekman

Investment Manager

Jeremy Knox

Senior Investment Director

Jun Qian

Head of Investments China and General Manager of Schroder Adveq Investment Management (Beijing) Co., Ltd.

Kathrin Keil

Alternatives Director

Lance Zhou

Investment Director

Lee A. Gardella

Head of Risk Management

Lee A. Gardella

Head of Risk Management

Maria Claudia Prieto

Head of Investments UK & Spain

Mark Nieuwenhuis

Legal Manager Private Investment Structures

Martyn Bott

Head of Finance

Martyn Bott

Head of Finance

Michael McLean

Investment Director

Nico Taverna

Head of the Adveq Secondaries program

Nils Rode

Chief Investment Officer, Member of the Investment Committee

Pascal Untersander

Risk Director

Page 1 of 2

Further reading


AEVI rakes in 30 mln euros - PE Hub


Schroder Adveq Study Finds US Family Offices Are Missing Key Opportunities in Private Equity


Schroders buys $7bn private equity firm Adveq

Mark Cobley


Xconomy: Rethink Robotics Adds $18M to Funding Pot Amid Automation Debate


Documentaries, videos and podcasts


Coller Institute Exclusive: The Performance of Private Equity

Feb 16, 2012

Mutmacher: Adveq

9 September 2013

Private Equity as a pension fund investment

May 10, 2016

Private equity: a responsible investor

Apr 5, 2013

Responsible Investing Growing in Importance - Driven by Ethical Principals, Institutional Investor Demands and Business Opportunities, Says New Survey from Caia and Adveq

Sven Liden, CEO and Head of Investor Relations, Adveq

Jul 1, 2014

Video: Adveq on Global Private Equity - Privcap

29 April 2014

Video: Pensions and Private Equity - Privcap

20 May 2014





Amal Therapeutics

Decibel Therapeutics

ImmunOs Therapeutics

Nohla Therapeutics

Pliant Therapeutics

Secured Mail


June 10, 2020
Company attracts three experienced industry executives to lead preclinical and clinical development as well as finance and operations


Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.